Introduction
Chronic lymphocytic leukemia (CLL) is one of the most common types of leukemia diagnosed in the Western Hemisphere, with 7,000 projected new cases in the United States in the year 2002 and a nationwide prevalence of approximately 50,000 persons (1) . CLL is characterized by disrupted apoptosis, as opposed to proliferation, leading to a gradual accumulation of leukemia cells eventually producing symptoms related to cytopenias or organomegaly (2, 3) . A small proportion of CLL patients have indolent disease, but the majority of patients either present with advanced stage disease or progress to the state of requiring treatment. The traditional therapeutic approach to CLL has been to utilize chlorambucil or fludarabine as initial therapy, although recently completed studies favor the latter with improved response rate and progression free survival over alkylator-based regimens (4, 5) .
Unfortunately, the majority of patients either fail to gain a complete response to fludarabine therapy or eventually relapse. This emphasizes the importance of focusing upon identification of new and specific therapies for CLL. Ideally, such treatments would work through activation of an apoptotic pathway different from standard regimens and would involve a specific drug target for which the minimally effective pharmacologic dose can be determined in vivo, thus avoiding unnecessary toxicity. Current treatments for CLL (e.g., fludarabine, cladribine, and alkylatorbased therapies) induce apoptosis via a mitochondria-dependent pathway involving activation of the protease caspase 9 (6-9). An alternative pathway for apoptosis involves cell death protease caspase 8 (FLICE) and is triggered by Fas (CD95) and other tumor necrosis factor (TNF) receptor family members. This cytokine-mediated pathway is generally not functional in B-cell CLL (9-
11). Attempts to increase expression of the Fas receptor on CLL cells with CD40 ligand (CD40L)
For personal use only. on . by guest www.bloodjournal.org From or bryostatin have been successful (12) , but these leukemic cells remain resistant to Fas-mediated ligation, implying a post receptor block to apoptosis. Since defects in the mitochondrial pathway of apoptosis are likely to exist in chemotherapy refractory CLL, identification of agents that exert their cytotoxic effect via the FAS/TNF receptor pathway of apoptosis would represent a major therapeutic advance for the treatment of patients with CLL and present a new opportunity for combination therapies.
Depsipeptide, a bicyclic depsipeptide currently in phase I clinical trials (13, 14) , is one such unique compound that has promise for CLL patient therapy. Our group recently reported (15) that this agent exhibits selective cytotoxicity toward CLL B-cells as compared to both normal mononuclear cells and bone marrow progenitor cells, with maximal cytotoxicity observed following a 4-hour drug exposure. Others have demonstrated that depsipeptide has selective cytotoxicity toward drug-resistant P388 leukemia cell lines as compared to non-resistant P388 cells, causing down-regulation of c-myc and morphologic normalization of Ras-transformed cells (16) (17) (18) (19) . In such dividing cell lines, it appears that depsipeptide mediates its effects through inhibition of the enzyme histone deacetylase (20). Indeed, histone acetylation and DNA methylation are two of the primary mechanisms that control gene transcription (21-25).
Inhibition of histone deacetylase (HDAC) in tumor cell lines potentially activates differentiationrelated or tumor suppressor genes by removing transcriptional repression (21, 22).
The relationship between alteration of histone acetylation and apoptosis by depsipeptide observed in non-dividing CLL cells is presently uncertain. We therefore studied histone acetylation and HDAC inhibition at depsipeptide concentrations that result in increased apoptosis
For personal use only. on April 10, 2017. by guest www.bloodjournal.org From in cultured CLL cells. We also further dissected the pathway of apoptosis utilized by depsipeptide and examined its treatment effect on levels of select apoptotic regulatory proteins.
Materials and Methods
Patients, Cell Separation, and Culture Conditions Approval for patient blood collection was obtained from The Ohio State University Institutional Review Board for these studies. Informed consent was provided according to the Declaration of Helsinki. Cells were procured from patients previously diagnosed with CLL as defined by the modified NCI criteria (26). All of the CLL patients had been without prior therapy for a minimum of two months. Mononuclear cells were isolated from the peripheral blood utilizing density gradient centrifugation (Ficoll-Paque Plus, Pharmacia Biotech, Piscataway, NJ). Isolation of mononuclear cells in this manner provides >90% positive co-expressing CD19 and CD5 clonal Blymphocytes. HeLa (CCL-2) and K562 (CCL-243) cell lines were obtained from American Type Culture Collection (ATCC, Manassas, VA). Cells were cultured in RPMI 1640 supplemented with 10% fetal bovine serum (FBS), 100 U/mL penicillin-G, 100 µg/ml streptomycin, and 2 mM L-glutamine (Life Technologies, Grand Island, NY). The broad caspase inhibitor Z-VAD-fmk was obtained from Kamiya Biochemical, Seattle, WA. Depsipeptide (FR901228 or NSC649890) and 2-F-ara-A were obtained from the Developmental Therapeutics Program, Division of Cancer Treatment, National Cancer Institute.
Apoptosis and Flow Cytometric Studies
Apoptosis was assessed in permeabilized cells using a phycoerythrin (PE)-labeled antiactive Caspase-3 polyclonal antibody (BD Pharmingen, San Diego, CA) that is specific for the For personal use only. on April 10, 2017. by guest www.bloodjournal.org From followed by a 20 min. centrifugation at maximum speed in a microfuge. 100% TCA was added to the supernatant to a final concentration of 20% TCA, and this was incubated at least 30 min. on ice. After centrifuging for 10 min. at maximum speed in a microfuge, cold acetone washes with shaking were used to remove salts from the pellet. Histones were then removed from the pellet by shaking using 0.5ml distilled water and were stored at -20C.
Western Blot Analysis
Whole cellular lysates were prepared as previously described (28). Total protein in each sample was quantified by the BCA method (Pierce, Rockford, IL). Lysates or extracted histones were analyzed by SDS-PAGE/immunoblotting with antibodies recognizing acetylated or methylated histones (Upstate, Lake Placid, NY) which are specific for various histone acetylation Samples were assayed in duplicate.
Histone Protein Substrate Preparation
Approximately 1 x 10 8 K562 cells were grown in RPMI media with additions as described above. Cells were pre-incubated in media with 200 ug/ml cycloheximide and 10 mM sodium butyrate 60 min at 37 o C in a 75-ml Corning tissue culture flask. Cells were then incubated in 10 ml of the above media with 300 uCi 3 H acetate (DuPont NEN, Boston MA) in a 50-ml centrifuge tube at 37 o . Cells were washed three times in 10 ml PBS + 10mM sodium butyrate. The histones were then isolated as described above. Acetylation of specific lysine residues on histone H3 and histone H4 has been associated with transcriptional activation, differentiation, and deposition of synthesized histones onto newly replicated DNA. We analyzed the histone acetylation patterns of three separate CLL patient samples treated with depsipeptide to quantify increases in global histone acetylation and to determine the lysine specificity of the acetylation. The pattern of lysine residue acetylation demonstrated increases in H4 K5, H4 K12 and H3 K9 acetylation in all patient specimens examined. A small change in H4 K8 was observed, and no changes in H4 K16 acetylation, H3 K14 acetylation, or H3 K9 methylation were observed. These findings suggest that inhibition of HDAC by depsipeptide induces acetylation of specific lysine residues on H3 and H4. We previously documented that a 4-hour incubation of CLL cells with depsipeptide induces apoptosis in a dose-dependent fashion (15) and have demonstrated ( Figure 3 ) that greatest inhibition of HDAC activity occurs at concentrations corresponding to where apoptosis is noted.
Apoptosis can occur through caspase-dependent and independent pathways. In the caspase- 
Depsipeptide Induced Apoptosis Occurs via the Tumor Necrosis Factor Receptor Pathway
Caspase-dependent apoptosis can be initiated through a variety of signal cascades, including the tumor necrosis factor (TNF) receptor (caspase 8) and mitochondria (caspase 9) pathway of apoptosis. These initiator caspases subsequently activate the effector caspase 3. To further characterize the apoptotic pathway utilized by depsipeptide to activate caspase 3, we examined whether the activity levels of either caspase 8 or caspase 9 increased following treatment, an indication of proteolytic processing and activation. Five patient samples were exposed to media or depsipeptide (0.38 µM) for four hours, and subsequently analyzed for caspases 8 and 9 activity. These data, depicted in Figure 5a , demonstrate that caspase 3 and caspase 8 activities increase over baseline at one day, but caspase 9 activity changes only minimally following treatment.
These data were confirmed by five separate in vitro experiments that showed no decrease in the non-cleaved caspase 9 but a dose-dependent decline in uncleaved caspase 8, generally corresponding to activation of this caspase following exposure to increasing concentrations of depsipeptide (Figure 5b ). This suggests that depsipeptide utilizes the TNF-receptor pathway of apoptosis to activate caspase 8, which leads to recruitment of caspase 3 and subsequent cleavage of PARP. While caspase 8 can cross-activate caspase 9 through cleavage of BID in some systems, we were unable to demonstrate either baseline or induced expression of BID (data not shown) in CLL cells as one other group has also reported (30). Furthermore, we did not detect caspase 9 processing, as shown in Figure 5b . (34, 35, 36) . RPD3 is the prototype of the human class I histone deacetylase class (HDAC 1-3) , suggesting that depsipeptide may target these enzymes (37) (38) (39) (40) . Understanding the role of specific histone deacetylase enzymes on these lysine residues and which of these are affected by specific histone deacetylase inhibitors will be important for eventual clinical exploitation of these agents in CLL and other diseases.
The mechanism by which depsipeptide and other histone deacetylase inhibitors induce cytotoxicity in CLL cells and other hematologic malignancies is still uncertain but may involve down-regulation of cytokines necessary for survival (41, 42) 
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Virtually all agents used in the treatment of cancer are most effective when administered in combination with other treatments. Depsipeptide targets a specific class of enzymes whose activity can be followed to prevent unnecessary dose escalation that may enhance toxicity without additional therapeutic benefit. Herein, we have provided in vitro validation of using the early pharmacodynamic endpoint of change in histone acetylation and inhibition of histone deacetylase, 
